Table 1.
A Select List of Covid-19 Vaccine Candidates in Clinical Development Under Public-Private-Partnership and Significant Public Investmenta.
| Candidate | Innovator | Large Pharma Partner | Public Investment (Millions in USD) | Clinical Status |
|---|---|---|---|---|
| mRNA-1273 | Moderna/NIAID | Catalent | $ 2455 | Phase 3 |
| AD1222 (ChAdOx1) | Oxford University | AstraZeneca | $ 1200 | Phase 3 |
| Ad26.CoV2.S | Harvard University | J & J | $ 1000 | Phase 1/2 |
| BNT162b1(2) (RNA-lipid vehicle) | BioNTech | Pfizer | $ 1950b | Phase 2/3 |
| CoVLP-Adjuvanted | Medicago | Sanofi/GSK | $ 2000 | Phase 1/2 |
| NVX-Co2373 Adjuvanted | Novavax | Not Disclosed | $2000 | Phase 1/2 |
a
The data in this table is constructed based on the published information under OWS (US Health and Human Services-HHS, 2020) and the ClinicalTrials.gov database as of Nov 2020.
b
The investment is in the form of 100 + 1300 million doses of vaccine purchase commitment while BNT162b1 is still under clinical development.